CriticalClass III antiarrhythmic×Atypical antipsychotic – dopamine and serotonin receptor antagonist
Updated · Methodology
Mechanism
Dronedarone can moderately prolong the Bazett heart-rate-corrected QT interval (QTc), by about 10 ms (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). The US label estimates a 15 ms increase at 400 mg twice daily with food (dronedarone label, US Food and Drug Administration, FDA). With risperidone, very rare cases of QT prolongation have been reported after marketing. QT prolongation has also been reported in overdose, and torsade de pointes with combined overdose of risperidone and paroxetine. In controlled trials, however, mean QT and QTc changes did not differ from placebo (risperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; risperidone label, FDA). CYP2D6 is the main enzyme that metabolises risperidone, with a smaller role for CYP3A4. Both risperidone and its active metabolite are substrates of the transporter P-glycoprotein (P-gp) (AEMPS). Dronedarone is a moderate CYP3A4 inhibitor and a strong P-gp inhibitor. It inhibits CYP2D6 weakly according to the European SmPC and moderately according to the US label (dronedarone SmPC, EMA; dronedarone label, FDA). Strong CYP3A4 or P-gp inhibitors can substantially raise the concentration of the active antipsychotic fraction of risperidone (AEMPS). The documents do not say how much dronedarone raises it.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Adverse reactions of risperidone include a fast or slow heart rate, atrial fibrillation, atrioventricular block, conduction disorders, QT prolongation and palpitations. The SmPC lists ventricular arrhythmia, ventricular fibrillation and tachycardia, sudden death, cardiac arrest and torsade de pointes as class effects of QT-prolonging antipsychotics (risperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Risperidone can cause a drop in blood pressure on standing, especially during initial dose titration (AEMPS). Adverse reactions of dronedarone include a slow heart rate and prolongation of the heart-rate-corrected QT interval. A proarrhythmic effect is possible with drugs that promote arrhythmias and with electrolyte disorders (dronedarone SmPC, European Medicines Agency, EMA).
Management
The combination is contraindicated. Both dronedarone documents contraindicate dronedarone with drugs that prolong the QT interval and can induce torsade de pointes. Their examples are phenothiazines, tricyclic antidepressants, certain macrolides and class I and III antiarrhythmics (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA; dronedarone label, US Food and Drug Administration, FDA). Risperidone is not among the examples. The editors include it in this group on the basis of its own Spanish SmPC. Its warnings section reports very rare cases of QT prolongation after marketing, and torsade de pointes has been reported with combined overdose with paroxetine (risperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Risperidone is used with caution with antiarrhythmics and other drugs that prolong QT, slow the heart rate or inhibit the hepatic metabolism of risperidone (AEMPS). According to its own documents, dronedarone prolongs QT, can slow the heart rate and inhibits the enzymes that metabolise risperidone (EMA, FDA). Dronedarone is also contraindicated with a heart rate below 50 beats per minute and with a Bazett heart-rate-corrected QT interval (QTc) of 500 ms or more. If any of its contraindications develops during treatment, dronedarone is stopped (EMA). Potassium or magnesium deficiency is corrected before dronedarone is started and during treatment. Monitoring, including an electrocardiogram (ECG), is recommended during treatment, and dronedarone is stopped if the QTc is 500 ms or more (EMA). If the two drugs are nevertheless taken together, the risperidone dose is reassessed when dronedarone is started or stopped, as with any strong P-glycoprotein (P-gp) inhibitor. Dronedarone belongs to this group (risperidone SmPC, AEMPS; dronedarone SmPC, EMA). With CYP2D6 inhibitors, the US risperidone label says to reduce the initial risperidone dose and not to exceed a final dose of 8 mg a day. The US dronedarone label calls dronedarone a moderate CYP2D6 inhibitor (risperidone and dronedarone labels, FDA). No document sets an interval between stopping one drug and starting the other. Dronedarone and its metabolite are fully cleared from plasma 2 weeks after stopping, and the half-life of the active antipsychotic fraction of risperidone is 24 hours (dronedarone SmPC, EMA; risperidone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- FDA: Risperdal (risperidone) prescribing information (2026)– FDA, DailyMed, Janssen Pharmaceuticals, setid 7e117c7e-02fc-4343-92a1-230061dfc5e0, version 45, effective 05/2026, sections 4, 6.1, 6.2, 7.1 (Table 18) and 10.1
- AEMPS: Ficha técnica: Risperidona (nº registro 60336), sección 4.5 (2025)– AEMPS, CIMA, nº registro 60336 (Risperdal 1 mg comprimidos recubiertos con película, Janssen-Cilag), revisión 05/2025, secciones 4.4, 4.5, 4.9 y 5.2